Baseline characteristics of participants presenting with or without peripheral artery disease (PAD)
Heart Protection Study Group J Vasc Surg 2007;45:645-54
Effects of simvastatin allocation on first major coronary event, stroke, or revascularization in participants
presenting with or without peripheral artery disease
Heart Protection Study Group J Vasc Surg 2007;45:645-54
Absolute effects of simvastatin allocation on 5-year rates of first major vascular events among participants subdivided by prior PAD
Heart Protection Study Group J Vasc Surg 2007;45:645-54
Effects of simvastatin allocation on major vascular events in prior disease subgroups
Heart Protection Study Group J Vasc Surg 2007;45:645-54
Effects of simvastatin allocation on first major vascular event in participants with or without PAD subdivided by other presenting features
Heart Protection Study Group J Vasc Surg 2007;45:645-54
Effects of simvastatin allocation on first and all major vascular events in participants with or without PAD
Heart Protection Study Group J Vasc Surg 2007;45:645-54
Effects of simvastatin allocation on first peripheral vascular event subdivided by presenting features
Heart Protection Study Group J Vasc Surg 2007;45:645-54
Average use of statin (study or non-study), and average plasma LDL cholesterol concentrations, during follow-up. Table online only
Heart Protection Study Group J Vasc Surg 2007;45:645-54
DISCUSSION
Heart Protection Study Group J Vasc Surg 2007;45:645-54
INVITED COMMENTARYWilliam R. Hiatt
Heart Protection Study Group J Vasc Surg 2007;45:645-54